Erika Vacchelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1441930/publications.pdf

Version: 2024-02-01

88 papers	12,098 citations	30070 54 h-index	49909 87 g-index
88 all docs	88 docs citations	88 times ranked	17894 citing authors

#	Article	IF	Citations
1	A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology, 2022, 11, 2059878.	4.6	3
2	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 2021, 11, 408-423.	9.4	28
3	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. OncoImmunology, 2021, 10, 1859064.	4.6	6
4	Trial watch: STING agonists in cancer therapy. OncoImmunology, 2020, 9, 1777624.	4.6	148
5	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2020, 9, 1777625.	4.6	91
6	Autophagy-mediated metabolic effects of aspirin. Cell Death Discovery, 2020, 6, 129.	4.7	17
7	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology, 2020, 9, 1796002.	4.6	63
8	No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19. OncoImmunology, 2020, 9, 1857112.	4.6	4
9	Chemical activation of SAT1 corrects diet-induced metabolic syndrome. Cell Death and Differentiation, 2020, 27, 2904-2920.	11.2	22
10	The ambiguous role of FPR1 in immunity and inflammation. OncoImmunology, 2020, 9, 1760061.	4.6	26
11	Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9, 1771143.	4.6	116
12	Contribution of annexin A1 to anticancer immunosurveillance. OncoImmunology, 2019, 8, e1647760.	4.6	27
13	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. OncoImmunology, 2019, 8, e1657375.	4.6	56
14	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
15	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. OncoImmunology, 2019, 8, e1498285.	4.6	25
16	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. OncoImmunology, 2018, 7, e1462431.	4.6	82
17	Organs on chip approach: a tool to evaluate cancer -immune cells interactions. Scientific Reports, 2017, 7, 12737.	3.3	69
18	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160.	16.8	410

#	Article	IF	Citations
19	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. OncoImmunology, 2016, 5, e1118600.	4.6	14
20	The ratio of CD8⁺/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. OncoImmunology, 2016, 5, e1218106.	4.6	50
21	Autophagy induction for the treatment of cancer. Autophagy, 2016, 12, 1962-1964.	9.1	50
22	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
23	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. Cancer Research, 2016, 76, 3122-3126.	0.9	47
24	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. OncoImmunology, 2016, 5, e1139275.	4.6	21
25	Trial Watchâ€"Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	4.6	52
26	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. OncoImmunology, 2016, 5, e1064581.	4.6	14
27	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. OncoImmunology, 2016, 5, e1149673.	4.6	136
28	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
29	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e985940.	4.6	47
30	Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. Cell Cycle, 2015, 14, 2399-2407.	2.6	27
31	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	4.6	237
32	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	12.6	367
33	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget, 2015, 6, 20840-20850.	1.8	50
34	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. OncoImmunology, 2015, 4, e988042.	4.6	27
35	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
36	Trial watch. OncoImmunology, 2014, 3, e29030.	4.6	51

#	Article	IF	Citations
37	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
38	Trial Watch. OncoImmunology, 2014, 3, e29179.	4.6	76
39	Trial Watch. OncoImmunology, 2014, 3, e27048.	4.6	69
40	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	4.6	223
41	Trial Watch. OncoImmunology, 2014, 3, e27297.	4.6	99
42	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. OncoImmunology, 2014, 3, e28473.	4.6	112
43	Coffee induces autophagy in vivo. Cell Cycle, 2014, 13, 1987-1994.	2.6	49
44	Regulation of Autophagy by Cytosolic Acetyl-Coenzyme A. Molecular Cell, 2014, 53, 710-725.	9.7	412
45	Trial Watch. OncoImmunology, 2014, 3, e27878.	4.6	134
46	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	30.7	823
47	Trial Watch. OncoImmunology, 2014, 3, e28344.	4.6	31
48	Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death and Differentiation, 2014, 21, 59-68.	11.2	83
49	Regulation of autophagy by stress-responsive transcription factors. Seminars in Cancer Biology, 2013, 23, 310-322.	9.6	215
50	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. Immunity, 2013, 38, 729-741.	14.3	572
51	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene, 2013, 32, 4995-5004.	5.9	108
52	Fluorescent Biosensors for the Detection of HMGB1 Release. Methods in Molecular Biology, 2013, 1004, 43-56.	0.9	12
53	Crosstalk between ER stress and immunogenic cell death. Cytokine and Growth Factor Reviews, 2013, 24, 311-318.	7.2	177
54	Trial watch. OncoImmunology, 2013, 2, e23803.	4.6	92

#	Article	IF	Citations
55	Current trends of anticancer immunochemotherapy. OncoImmunology, 2013, 2, e25396.	4.6	26
56	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. OncoImmunology, 2013, 2, e24568.	4.6	75
57	Trial watch. OncoImmunology, 2013, 2, e23082.	4.6	130
58	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle, 2013, 12, 417-421.	2.6	26
59	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150
60	Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology, 2013, 2, e26494.	4.6	50
61	Trial watch. OncoImmunology, 2013, 2, e22789.	4.6	92
62	Trial watch. OncoImmunology, 2013, 2, e23510.	4.6	153
63	Trial Watch. OncoImmunology, 2013, 2, e26621.	4.6	101
64	Trial Watch. OncoImmunology, 2013, 2, e24238.	4.6	58
65	Trial Watch. OncoImmunology, 2013, 2, e24850.	4.6	49
66	Trial Watch. OncoImmunology, 2013, 2, e25595.	4.6	83
67	Trial Watch. OncoImmunology, 2013, 2, e25238.	4.6	132
68	Trial watch. OncoImmunology, 2013, 2, e24612.	4.6	175
69	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology, 2012, 1, 894-907.	4.6	194
70	Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle, 2012, 11, 3472-3480.	2.6	32
71	Loss-of-function alleles ofP2RX7andTLR4fail to affect the response to chemotherapy in non-small cell lung cancer. OncoImmunology, 2012, 1, 271-278.	4.6	36
72	Anticancer activity of cardiac glycosides. OncoImmunology, 2012, 1, 1640-1642.	4.6	89

#	Article	IF	Citations
73	Trial watch. OncoImmunology, 2012, 1, 179-188.	4.6	104
74	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	4.6	110
75	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy, 2012, 8, 413-415.	9.1	90
76	Trial Watch. OncoImmunology, 2012, 1, 699-739.	4.6	184
77	Trial Watch. OncoImmunology, 2012, 1, 306-315.	4.6	70
78	Trial Watch. OncoImmunology, 2012, 1, 493-506.	4.6	86
79	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle, 2012, 11, 3851-3860.	2.6	91
80	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122
81	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	6.4	0
82	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	4.6	152
83	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	4.6	103
84	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	4.6	203
85	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Science Translational Medicine, 2012, 4, 143ra99.	12.4	367
86	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science, 2011, 334, 1573-1577.	12.6	1,159
87	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	2.8	46
88	Mitochondrial gateways to cancer. Molecular Aspects of Medicine, 2010, 31, 1-20.	6.4	239